Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

The incorporation of tyrosine kinase inhibitors (TKIs) into chemotherapy regimens has significantly improved the outcomes of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Second and third generation TKIs with increased potency against BCR-ABL1 and enhanced activity against ABL1 kinase domain mutations have been evaluated in a number of studies showing significant promise. In particular, ponatinib, a potent pan-BCR-ABL1 TKI capable of overcoming the T315I mutation, is of significant interest in the treatment of Ph+ ALL, as a number of reports have shown a high incidence of T315I mutants at relapse.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research